Binds Eukaryotic Cell Or Component Thereof Or Substance Produced By Said Eukaryotic Cell (e.g., Honey, Etc.) Patents (Class 424/172.1)
  • Patent number: 10987387
    Abstract: The invention provides compositions comprising bacterial strains for treating and preventing cancer.
    Type: Grant
    Filed: November 21, 2019
    Date of Patent: April 27, 2021
    Assignee: 4D Pharma Research Limited
    Inventors: Imke Elisabeth Mulder, Emma Raftis, Delphine Louise Claudette Caly, Emma Elizabeth Clare Hennessy
  • Patent number: 10948492
    Abstract: The present invention is based on the identification of novel biomarkers predictive of responsiveness of esophagogastric cancers to inhibitors of the PD-1 pathway.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: March 16, 2021
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Adam Bass, Sarah Derks, Gordon J. Freeman, Scott J. Rodig
  • Patent number: 10941195
    Abstract: The present invention provides antibodies and antigen binding fragments thereof that bind to human Follistatin-Like-3 (FSTL3) protein, compositions comprising such antibodies, and methods of making and using such antibodies.
    Type: Grant
    Filed: October 4, 2017
    Date of Patent: March 9, 2021
    Inventor: Alan Schneyer
  • Patent number: 10898550
    Abstract: A method of treating root avulsion injury in a subject in need thereof includes administering to the subject a therapeutic agent that inhibits one or more of catalytic activity, signaling, and function of PTP?.
    Type: Grant
    Filed: April 11, 2019
    Date of Patent: January 26, 2021
    Inventors: Jerry Silver, Bradley T. Lang, Jared M. Cregg, Yi-Lan Weng, Heng Li, Wutian Wu
  • Patent number: 10870635
    Abstract: The present invention relates to compounds of Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein X, Y, Z, Q, W, m, u, ring (A), R2, R3, R4, R5 and R6, are as defined in the specification and claims. The present invention provides a pharmaceutical composition containing the compounds of Formula (I) and a therapeutic method of treating and/or preventing Downs syndrome, 3-amyloid angiopathy, disorders associated with cognitive impairment, Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegenerative diseases, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, Alzheimer's disease and/or Down syndrome, age-related macular degeneration (AMD), glaucoma, olfactory function impairment, traumatic brain injury, progressive muscle diseases, Type II diabetes mellitus and cardiovascular diseases (stroke).
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: December 22, 2020
    Inventors: Madhu Cherukury, Hsiao-Wen Lin, Shu Chieh Yu, Riping Phang, Yesudoss Christu Rajan, Diane Dan-Shya Tang-Liu, Andrew D. White, Thomas Malone, Richard Beresis
  • Patent number: 10864197
    Abstract: Methods of treatment comprising administering a compound having structure (I), or a pharmaceutically acceptable salt thereof, or administering a pharmaceutical composition comprising the compound of structure (I) or pharmaceutically acceptable salt thereof, are provided.
    Type: Grant
    Filed: May 22, 2020
    Date of Patent: December 15, 2020
    Assignee: RETROPHIN, INC.
    Inventors: Radko Komers, Alvin Shih
  • Patent number: 10786504
    Abstract: This present disclosure relates to a method of treating autoimmune, respiratory and/or inflammatory diseases or conditions, e.g., asthma, COPD, rheumatoid arthritis and idiopathic Pulmonary Fibrosis (IPF). The method comprises administering a dual PI3K delta and gamma inhibitor and a corticosteroid. The present invention also relates to pharmaceutical compositions containing a dual PI3K delta and gamma inhibitor and a corticosteroid.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: September 29, 2020
    Assignee: Rhizen Pharmaceuticals SA
    Inventors: Swaroop K. V. S. Vakkalanka, Srikant Viswanadha
  • Patent number: 10787711
    Abstract: Provided is an approach for differentially determining the histological type of a lung cancer lesion objectively and rapidly with high accuracy. A method for differentially assessing a lesion in a lung cancer patient as squamous cell carcinoma or adenocarcinoma, comprising a step of measuring an expression level of an expression product of at least one DNA comprising a transcription start site in a biological sample collected from the lesion, wherein the DNA comprises a base at an arbitrary position in the transcription start site and at least one or more bases located immediately downstream thereof in any of nucleotide sequences represented by SEQ ID NOs: 1 to 213, and the transcription start site is a region wherein both ends thereof are defined by the first base and the 101st base counted from the 3? end in any of the nucleotide sequences represented by SEQ ID NOs: 1 to 213.
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: September 29, 2020
    Inventors: Kazuya Takamochi, Kenji Suzuki, Tsuyoshi Saito, Kieko Hara, Keiko Mitani, Kaoru Mogushi, Yoshihide Hayashizaki, Masayoshi Ito, Hideya Kawaji, Hiroko Oomiya, Yasunari Yamanaka
  • Patent number: 10711067
    Abstract: The present disclosure relates, in general, to methods of treating or preventing post-prandial hypoglycemia after gastric bypass surgery using a negative modulator antibody that binds to the insulin receptor and modulates the action of insulin at the insulin receptor.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: July 14, 2020
    Assignee: XOMA (US) LLC
    Inventors: Kirk W. Johnson, Rajneesh Nath, Paul Rubin
  • Patent number: 10633434
    Abstract: The present invention provides monoclonal antibodies that bind to the complement factor 5 (C5) protein, and methods of use thereof. In various embodiments of the invention, the antibodies are fully human antibodies that bind to C5 protein. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing C5 activity, thus providing a means of treating or preventing a C5-related disease or disorder in humans. In some embodiments, the invention provides for an anti-C5 antibody that has improved pharmacokinetic and pharmacodynamic properties, e.g., a half-life of more than 10 days.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: April 28, 2020
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Ying Hu, Adrianna Latuszek, Carmelo Romano, William Olson
  • Patent number: 10620211
    Abstract: This disclosure relates to methods of assaying and scoring PD-L1 expression in tumors. Tumor samples are labeled with an antibody or antibody fragment that specifically binds to human PD-L1 and binding is detected. Binding intensity is compared to background, and tumor cells having membrane staining above background are counted. The percentage of tumor cells containing membrane staining of PD-L1 is determined and the tumor is classified as “PD-L1 positive” if the percentage of tumor cells falls above a predefined level.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: April 14, 2020
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Amita T. Mistry, Constantine M. Sabalos
  • Patent number: 10617757
    Abstract: The present disclosure provides methods of treating multiple myeloma in an individual, the methods comprising genotyping an HLA allele and a KIR allele in the individual; and, depending on the outcome of the genotyping, administering a multiple myeloma therapy to the individual. In some embodiments, the multiple myeloma therapy comprises an anti-CD38 antibody, lenalidomide, and dexamethasone. The present disclosure provides methods for selecting a multiple myeloma patient for a multiple myeloma therapy. The present disclosure provides methods for identifying a multiple myeloma patient as likely to experience a beneficial clinical outcome from a multiple myeloma therapy.
    Type: Grant
    Filed: August 4, 2015
    Date of Patent: April 14, 2020
    Assignee: The Regents of the University of California
    Inventor: Jeffrey M. Venstrom
  • Patent number: 10550196
    Abstract: Humanized antibodies, capable of specific binding to human CEACAM1 molecules containing human-to-murine back-mutations in non-CDR variable regions, and their encoding polynucleotide sequences are provided. Pharmaceutical compositions comprising these antibodies as well as methods of their use in treating and diagnosing cancer and other conditions are also provided.
    Type: Grant
    Filed: April 27, 2015
    Date of Patent: February 4, 2020
    Assignee: Famewave Ltd.
    Inventors: Tehila Ben-Moshe, Yair Sapir, Ilana Mandel, Gal Markel, Jacob Schachter, Rona Ortenberg, Francis Joseph Carr, Robert George E. Holgate, Timothy David Jones
  • Patent number: 10543236
    Abstract: A homeopathic pain topical analgesic composition based on snake venom is disclosed. The study product also contained of Arnica montana, a homeopathic remedy most frequently used for fractures, bruises, and muscle strains due to its analgesic and anti-inflammatory effects. The composition also contained a penetrant component to enhance penetration of the ingredients as well as an analgesic/anti-inflammatory component. The snake venoms used may include those of Naja naja, Crotalus horridus and Lachesis muta. A clinical study of a product formulated in this way was effective in promoting relief from muscle pain and discomfort.
    Type: Grant
    Filed: July 28, 2014
    Date of Patent: January 28, 2020
    Inventors: William S. Carlson, Michael J. Rourk, Holly E. Carpenter
  • Patent number: 10398672
    Abstract: Aspects of the disclosure relate to methods that involve activating the Protein Kinase A (PKA) pathway to induce cancer stem cells (CSCs) to undergo a mesenchymal to epithelial transition. Methods provided herein are useful, in some embodiments, because they render CSCs amenable to treatment with conventional cancer therapies. In some embodiments, methods are provided that involve assaying PKA pathway activity to identify compounds that selectively target CSCs.
    Type: Grant
    Filed: April 29, 2015
    Date of Patent: September 3, 2019
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Diwakar Pattabiraman, Brian Bierie, Wai Leong Tam, Robert A. Weinberg
  • Patent number: 10369197
    Abstract: The present invention relates to the use of a CD24 protein for lowering low-density lipoprotein cholesterol levels, treating and preventing atherosclerosis, and for reducing risk of cardiovascular disease.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: August 6, 2019
    Assignee: OncoImmune, Inc.
    Inventors: Yang Liu, Pan Zheng
  • Patent number: 10370643
    Abstract: The current disclosure describes methods of expanding precursor cells for hematopoietic transplantation in subjects. The methods culture precursor cells in media containing an immobilized high molecular weight LILRB2 agonist or an LILRB2 agonist in combination with a Notch agonist. The expanded cells can be used to treat a variety of hematopoietic disorders.
    Type: Grant
    Filed: May 21, 2015
    Date of Patent: August 6, 2019
    Assignees: Fred Hutchinson Cancer Research Center, Board of Regents of the University of Texas System
    Inventors: Irwin D. Bernstein, Chengcheng Zhang, Mi Deng, Zhigang Lu, Junke Zheng
  • Patent number: 10336793
    Abstract: The present invention relates to, in part, compositions comprising improved flagellin derived constructs and methods of using for vaccination, including adjuvants comprising flagellin-based agents.
    Type: Grant
    Filed: July 30, 2015
    Date of Patent: July 2, 2019
    Inventors: Andrei V. Gudkov, Vadim Mett, Vadim Krivokrysenko
  • Patent number: 10335491
    Abstract: This invention relates, e.g., to a molecular delivery system comprising A. a substrate having a nanostructured surface region which comprises a plurality of nanostructures and, covalently attached to the substrate, multiple copies of a first member of a binding pair; and B. at least one vector nanoparticle which comprises, encapsulated therein, a molecule of interest, and on its surface, multiple copies of second member of the binding pair. Methods of using the molecular delivery system to deliver a molecule of interest to a cell are also described.
    Type: Grant
    Filed: July 23, 2012
    Date of Patent: July 2, 2019
    Assignees: The Regents of the University of California, National Institutes of Health (NIH)
    Inventors: Hsian-Rong Tseng, Hao Wang, Kuan-Ju Chen
  • Patent number: 10314904
    Abstract: The present invention provides methods for enhancing the efficacy and/or safety of a vaccine. In certain embodiments, the invention provides methods to increase or potentiate the immune response to a vaccine in a subject in need thereof. The methods of the present invention comprise administering to a subject in need thereof an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody in combination with said vaccine. In certain embodiments, the methods of the present invention are used to afford enhanced protection to an infectious disease such as whooping cough.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: June 11, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lisa Purcell, Neil Graham, Andrew J. Murphy, Robert Evans
  • Patent number: 10287346
    Abstract: The present invention aims to obtain an anti-repulsive guidance molecule a (RGMa) antibody having a high binding activity and few side effects which can be used as a medicine for preventing, treating, or preventing the relapse of neurological or immunological diseases. The problem is solved by providing an isolated RGMa binding protein which does not inhibit binding between RGMa and neogenin but neutralizes the neurite outgrowth inhibiting activity of RGMa, preferably by providing an anti-RGMa antibody which has complementarity determining regions having amino acid sequences of SEQ ID NOS: 30-35 or SEQ ID NOS: 36-40 in Sequence Listing, and SFG.
    Type: Grant
    Filed: April 27, 2016
    Date of Patent: May 14, 2019
    Inventors: Motonori Hashimoto, Toshihide Yamashita
  • Patent number: 10286048
    Abstract: This disclosure relates to materials and methods useful for vaccinating mammals against the effects of envenomation by venomous organisms (including the Western Rattlesnake) by making use of venom from multiple distinct populations, subspecies or species of the organism, to make a vaccine more broadly protective against other populations, subspecies or species. This disclosure also relates to a method for determining which organisms which are capable of envenomation should be pooled for optimizing the coverage and efficacy of a vaccine which is produced from the venoms (or toxoid derivatives) in the combination.
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: May 14, 2019
    Inventors: James G. McCabe, James Brockett, Thomas M. McCabe
  • Patent number: 10241115
    Abstract: The present disclosure describes an IHC assay for detecting and quantifying spatially proximal pairs of PD-1-expressing cells (PD-1+ cells) and PD-Ligand-expressing cells (PD-L+ cells) in tumor tissue, and the use of the assay to generate proximity biomarkers that are predictive of which cancer patients are most likely to benefit from treatment with a PD-1 antagonist. The disclosure also provides methods for testing tumor samples for the proximity biomarkers, as well as methods for treating subjects with a PD-1 antagonist based on the test results.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: March 26, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Robert H. Pierce, Jennifer H. Yearley, Scott P. Turner, Belma Dogdas, Ansuman Bagchi
  • Patent number: 10213513
    Abstract: This document provides methods and materials related to treating myelomas. For example, methods and materials relating to the use of a composition containing albumin-containing nanoparticle/antibody complexes (e.g., ABRAXANE®/anti-CD38 polypeptide antibody complexes) to treat myelomas are provided.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: February 26, 2019
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Svetomir N. Markovic, Wendy K. Nevala
  • Patent number: 10208129
    Abstract: An erbB2 antibody is provided that binds preferentially to disease cells having an erbB2 density greater than a normal erbB2 density. The erbB2 antibody comprises a heavy chain and a light chain. Each chain has a constant region and a variable region. Each variable region comprises framework regions and complementarity determining regions (CDRs), wherein the CDRs have an amino acid sequence set forth below: For the heavy chain: CDR1 GFNIKDTYIH (SEQ ID No. 1) CDR2 RIYPTNGY57TR59 YADSVKG (SEQ ID No. 2) CDR3 WGGDGFYAMDY (SEQ ID No. 3) For the light chain: CDR1 RASQDVN30TAVA (SEQ ID No. 4) CDR2 SASF53LYS (SEQ ID No. 5) CDR3 QQHY92TTPPT (SEQ ID No. 6). At least one of Y57, R59, N30, F53, and Y92 is substituted by an amino acid that confers on said antibody a reduced erbB2 binding affinity (Kd) that is in the range from 0.1 nM to 100 nM. The substitution is other than N30A, F53N, Y92A and Y92F when there is a single substitution in the antibody light chain.
    Type: Grant
    Filed: December 2, 2011
    Date of Patent: February 19, 2019
    Assignee: National Research Council of Canada
    Inventors: Ilia Alexandre Tikhomirov, Maria L. Jaramillo, Maureen D. O'Connor-McCourt, Traian Sulea, Renald Gilbert, Bruno Gaillet, Jason Baardsnes
  • Patent number: 10202463
    Abstract: Isolated pluralities of T cells which recognize at least one epitope of an intestinal cancer antigen or CNS cancer antigen and pharmaceutical compositions comprising the same are disclosed. Methods of making a plurality of T cells that recognize at least one epitope of an intestinal cancer antigen or CNS cancer antigen are also disclosed. Methods of treating an individual who has been diagnosed with cancer of a mucosal tissue or preventing such cancer in an individual at elevated risk are disclosed as are nucleic acid molecules that comprise a nucleotide sequence that encode proteins that recognize at least one epitope of an intestinal cancer antigen or CNS cancer antigen and T cells comprising such nucleic acid molecules.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: February 12, 2019
    Assignee: Thomas Jefferson University
    Inventors: Scott A. Waldman, Adam E. Snook, Michael S. Magee
  • Patent number: 10166251
    Abstract: The invention provides methods of inhibiting epigenetic gene silencing in a cell expressing NPM/ALK or decreasing NPM/ALK content in a cell, by contacting a cell with an agent capable of increasing the concentration of Stat5a protein or its functional analog. Further, the invention provides a method of treating malignancies expressing oncogenic kinase by administering to a patient affected with a malignancy an agent capable of increasing the concentration of Stat5a protein or its epigenetically silenced functional tumor suppressor analog in a malignant cell. Finally, it provides a method to diagnose malignancy and monitor patient's response to therapy by analysis of the degree of DNA methylation of the gene encoding for Stat5a or its analog, their mRNA, or protein.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: January 1, 2019
    Inventors: Mariusz A. Wasik, Qian Zhang
  • Patent number: 10160805
    Abstract: Methods and compositions for treating inflammatory bowel disease by promoting mucosal healing in the gastrointestinal (GI) tract are encompassed herein. More particularly, methods and compositions described herein relate to agents that activate mononuclear phagocytes (MNPs) in the GI tract and, in turn, regulate the activity of interleukin (IL)-22-producing group 3 innate lymphoid cells (ILC3) in close proximity thereto.
    Type: Grant
    Filed: July 13, 2015
    Date of Patent: December 25, 2018
    Assignees: New York University, Cornell University
    Inventors: Randy S. Longman, Gretchen E. Diehl, Dan R. Littman
  • Patent number: 10144932
    Abstract: Methods of treating movement disorders by reducing the activity of Nurr1 are disclosed. These methods are particularly applicable to subjects suffering from Parkinson's disease who have either developed levodopa-induced dyskinesia (LID) or are at risk of developing LID. In some aspects, the invention relates to a method for treating a movement disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition, wherein said composition reduces the activity of a nuclea receptor related 1 protein (“Nurr1”). In some embodiments, the movement disorder is a dyskinesia. The movement disorder may be a levodopa-induced dyskinesia.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: December 4, 2018
    Assignee: Board of Trustees of Michigan State University
    Inventors: Fredric P. Manfredsson, Jack W. Lipton, Nicholas Kanaan, Timothy Collier, Kathy Steece-Collier, Caryl E. Sortwell
  • Patent number: 10137195
    Abstract: The present invention generally provides a therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, in particular cancer diseases such as gastroesophageal cancer. Data are presented demonstrating that administration of an anti-CLDN18.2 antibody to human patients with gastroesophageal cancer is safe and well-tolerated up to a dose of at least 1000 mg/m2. Furthermore, data are presented demonstrating that the antibody is fully functional in these patients to execute anti-tumor cell effects and evidence for antitumoral activity was obtained.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: November 27, 2018
    Assignees: Ganymed Pharmaceuticals GmbH, TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gGmbH
    Inventors: Ugur Sahin, Özlem Türeci
  • Patent number: 10058543
    Abstract: Methods and compositions are provided for the treatment of familial exudative vitreoretinopathy (FEVR) and retinopathy of prematurity (ROP) through the administration of a therapeutically effective amount of a Sphingosine-1-phosphate receptor type 2 (S1PR2) inhibitor.
    Type: Grant
    Filed: June 1, 2015
    Date of Patent: August 28, 2018
    Inventor: Christopher McMaster
  • Patent number: 10040855
    Abstract: Antibody formulations are described comprising a mixture of an anti-?4?7 antibody, an antioxidant or chelator, and at least one free amino acid. The disclosed formulations may have improved stability, reduced aggregate formation, or both. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-?4?7 antibody in vivo.
    Type: Grant
    Filed: May 2, 2012
    Date of Patent: August 7, 2018
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Willow Diluzio, Phoung M. Nguyen, Csanad M. Varga, Vaithianathan Palaniappan, Jason Brown
  • Patent number: 10035861
    Abstract: The present invention provides compositions and methods relating to or derived from anti-IGF-1R antibodies. In particular embodiments, the invention provides fully human, humanized, or chimeric anti-IGF-1R antibodies that bind human IGF-1R, IGF-1R-binding fragments and derivatives of such antibodies, and IGF-1R-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF-1R-related disorders or conditions.
    Type: Grant
    Filed: November 24, 2014
    Date of Patent: July 31, 2018
    Assignee: Amgen Inc.
    Inventors: Frank J. Calzone, Rajendra V. Deshpande, Mei-Mei Tsai
  • Patent number: 10035853
    Abstract: Provided are novel antibody drug conjugates (ADCs), and methods of using such ADCs to treat proliferative disorders.
    Type: Grant
    Filed: February 29, 2016
    Date of Patent: July 31, 2018
    Assignee: AbbVie Stemcentrx LLC
    Inventors: William Robert Arathoon, Ishai Padawer, Luis Antonio Cano, Vikram Natwarsinhji Sisodiya, Karthik Narayan Mani, David Liu
  • Patent number: 10017475
    Abstract: Combretastatins analog compounds and their pharmaceutically acceptable salts are presented, as well as pharmaceutical compositions comprising the combretastatin analog compounds and uses of the combretastatin analog compounds, either alone or in combination with at least one additional therapeutic agent, in the treatment of cancer, and in particular cancer presenting as metastatic tumors.
    Type: Grant
    Filed: March 26, 2015
    Date of Patent: July 10, 2018
    Inventors: Guangdi Wang, Shilong Zheng, Qiu Zhong, Qiang Zhang
  • Patent number: 10004780
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of age-related macular degeneration (AMD). In particular the present invention relates to RdCVFL polypeptide or polynucleotide for use in the treatment of AMD.
    Type: Grant
    Filed: October 17, 2013
    Date of Patent: June 26, 2018
    Inventors: Thierry Leveillard, Jose-Alain Sahel, Therese Cronin, Leah Byrne, Ram Fridlich
  • Patent number: 9933439
    Abstract: Embodiments of the invention provide method and devices for predicting the likelihood of acute appendicitis without invasive exploratory medical procedures. Several protein biomarkers: leucine-rich ?-2-glycoprotein (LRG); S100-A8 (calgranulin); ?-1-acid glycoprotein 1 (ORM); plasminogen (PLG); mannan-binding lectin serine protease 2 (MASP2); zinc-?-2-glycoprotein (AZGP1); Apolipoprotein D (ApoD); and ?-1-antichymotrypsin (SERPINA3); are increased in the urine of patients with appendicitis. The method and devices comprise detecting the levels of these biomarkers and comparing with reference levels found in healthy individuals.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: April 3, 2018
    Inventors: Alex Kentsis, Hanno Steen, Richard Bachur
  • Patent number: 9890213
    Abstract: Methods for treating diseases associated with chemokine (C-X-C motif) ligand 13 (CXCL13) expression, including certain autoimmune and inflammatory diseases such as Sjogren's syndrome are provided herein. The methods comprise administering to a subject in need thereof an effective amount of an agent that inhibits CXCL13 activity. According to aspects of the invention illustrated herein, there is provided a method of treating, preventing, or reducing the exacerbation of a B-cell-mediated inflammatory condition in a subject, including administering to a subject an effective amount of an isolated binding molecule which specifically binds to CXCL13, wherein said molecule prevents or inhibits CXCL13 activity.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: February 13, 2018
    Assignee: Vaccinex, Inc.
    Inventors: Ernest S. Smith, Maurice Zauderer
  • Patent number: 9834607
    Abstract: Described herein are novel compositions comprising bispecific and multispecific polypeptide agents, and methods using these agents for targeting cells, such as functionally exhausted or unresponsive immune cells, that co-express the inhibitory receptors PD-1 and TIM-3. These compositions and methods are useful for the treatment of chronic immune conditions, such as persistent infections or cancer.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: December 5, 2017
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Vijay K. Kuchroo, Ana C. Anderson
  • Patent number: 9816999
    Abstract: A method for diagnosing the development of a tissue injury in a subject comprising administering a sample of neoantibodies to the subject's tissue for the purpose of detecting the presence of neoepitopes bearing complement proteins.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: November 14, 2017
    Assignee: Novelmed Therapeutics, Inc.
    Inventor: Rekha Bansal
  • Patent number: 9815898
    Abstract: Antibody molecules that specifically bind to PD-1 are disclosed. The anti-PD-1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.
    Type: Grant
    Filed: May 15, 2017
    Date of Patent: November 14, 2017
    Inventors: Gordon James Freeman, Arlene Helen Sharpe, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Anne Sabatos-Peyton, Hwai Wen Chang, Gerhard Johann Frey
  • Patent number: 9771417
    Abstract: The present invention relates to monoclonal antibodies binding to human angiopoietin-like 4 protein (hereinafter, sometimes referred to as “ANGPTL4”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: September 26, 2017
    Assignee: NOVARTIS AG
    Inventors: John Trauger, Andrei Igorevich Voznesensky
  • Patent number: 9758594
    Abstract: The present invention relates to a multivalent antibody comprising multiple heavy chain variable regions of antibody linked to each other via a linker comprising an amino acid sequence encoding an immunoglobulin domain or a fragment thereof.
    Type: Grant
    Filed: April 27, 2009
    Date of Patent: September 12, 2017
    Inventor: Nobuaki Takahashi
  • Patent number: 9709563
    Abstract: Passivated substrates are provided for use in assays, comprising at least one covalently bonded ligand having specific binding activity for a molecule, and at least one covalently bonded blocking agent, wherein said ligand is directly bonded to the substrate surface. In certain embodiments, the ligand and blocking agent are covalently bonded only to the substrate surface, and not directly bonded to each other. In certain other embodiments, the ligand and blocking agent have at least one additional covalent bond to one another. Methods for preparing and using passivated substrates in bioassays are also provided.
    Type: Grant
    Filed: March 12, 2010
    Date of Patent: July 18, 2017
    Assignee: Agilent Technologies, Inc.
    Inventor: Roderick Nicholas Hobbs
  • Patent number: 9708590
    Abstract: The present invention provides the three-dimensional structure of human ?-N-acetylglucosaminidase (NAGLU) protein. This crystallographic information is useful in the identification and development of novel binding compounds of NAGLU, NAGLU mutants, for example, those associated with Sanfilippo syndrome type B (mucopolysaccharidosis III B (MPS III-B)), and other NAGLU family members (family 89 ?-N-acetylglucosaminidase) which may modulate the activity and/or stability of mutated NAGLU. Such compounds may be useful for the treatment of Sanfilippo syndrome type B (mucopolysaccharidosis III B (MPS III-B)).
    Type: Grant
    Filed: July 7, 2014
    Date of Patent: July 18, 2017
    Assignee: Shire Human Genetic Therapies, Inc.
    Inventors: Muthuraman Meiyappan, Michael F. Concino, Angela W. Norton
  • Patent number: 9688747
    Abstract: The present invention features methods and compositions for the generation and use of conformation-specific anti-bodies or fragments thereof.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: June 27, 2017
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Kun Ping Lu, Xiao Zhen Zhou
  • Patent number: 9683040
    Abstract: The present invention relates to an antibody having an anti-angiogenesis activity. More specifically, the present invention relates to an antibody against ROBO4 and a pharmaceutical composition containing the antibody. An object of the present invention is to provide an anti-ROBO4 antibody having an anti-angiogenesis effect, a pharmaceutical composition or the like comprising the antibody, a method for suppressing angiogenesis using the antibody, etc. Another object of the present invention is to provide a method for producing the antibody. The antibody of the present invention activates the downstream signal of ROBO4 and has a suppressive activity against cell migration induced by VEGF or bFGF. The antibody of the present invention also exhibits an anti-angiogenesis effect in in-vivo models.
    Type: Grant
    Filed: April 26, 2013
    Date of Patent: June 20, 2017
    Inventors: Yoshitaka Isumi, Toshiyuki Sato, Jun Hasegawa, Tatsuya Inoue
  • Patent number: 9623115
    Abstract: Disclosed herein are compositions and methods of use of dock and lock (DNL) complexes comprising a first antibody or fragment that binds to a stem cell antigen and a second antibody or fragment thereof that binds to an antigen on a diseased or damaged tissue or organ. The DNL complexes are of use for targeting stem cells to diseased or damaged organs or tissues and may be used to treat a variety of diseases or conditions that are responsive to stem cell therapy.
    Type: Grant
    Filed: November 14, 2011
    Date of Patent: April 18, 2017
    Assignee: IBC Pharmaceuticals, Inc.
    Inventors: Chien-Hsing Chang, David M. Goldenberg
  • Patent number: 9598733
    Abstract: Seven protective alleles for IgA nephropathy have been discovered that can be identified by analyzing a DNA sample for seven respective SNPs. A method is provided for identifying and treating subjects at risk of developing IgA neuropathy based on a new seven-SNP genetic risk score. Also provided are screening methods to identify compounds that bind to and reduce the expression or biological activity of a either CFHR1 or CFHR3.
    Type: Grant
    Filed: February 17, 2012
    Date of Patent: March 21, 2017
    Assignees: The Trustees of Columbia University in the City of New York, Yale University
    Inventors: Ali Gharvari, Krzysztof Kiryluk, Richard Lifton
  • Patent number: 9587032
    Abstract: The present invention provides novel IgE antibodies useful for inhibiting or preventing metastatic cancer. Also provided are methods to inhibit tumor metastasis by modulating the activity of at least one non-tumor cell, treating a patient to inhibit or prevent tumor metastases of a primary solid tumor, treating metastatic carcinoma, reducing metastasis of carcinoma cells, and reducing the growth kinetics of a primary solid tumor or a metastasized cell or tumor.
    Type: Grant
    Filed: July 11, 2013
    Date of Patent: March 7, 2017
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Joseph A. Mollick, Pearline Teo, Paul J. Utz